Estimated cost efficacy of systemic treatments that are approved by the US Food and Drug Administration for the treatment of moderate to severe psoriasis

Cutting Edge: Selective Oral ROCK2 Inhibitor Reduces Clinical Scores in Patients with Psoriasis Vulgaris and Normalizes Skin Pathology via Concurrent Regulation of IL-17 and IL-10

“…Pharmacokinetic analysis was performed at selected study sites, and peripheral blood samples were collected from a subgroup of subjects from each cohort at the following time points: predose (time 0) and 1, 2, 4,6,8,12,16,18, and 24 h after dosing on day 1 of month 1. For cytokine evaluation, peripheral blood samples were collected from all patients at baseline (predose), after 4, 8, and 12 wk of treatment with KD025, and at the follow-up visit, that is, 30 d after the last dosing with the drug.…”

“…However, the use of aforementioned biologics for psoriasis and other chronic autoimmune disorders can be limited by long-term safety issues, such as an increase rate of infections due to the central role of IL-17 in protection against Candida (8-10). Additionally, biologic therapies are costly compared with traditional systemic therapy and are administrated via injection, which may limit patient acceptability (11,12). Thus, the development of new oral therapies remains important and can offer an alternative risk-benefit profile via modulation of specific disease-associated cellular pathways.…”

The infliximab biosimilar in the treatment of moderate to severe plaque psoriasis

“…1,2 Cheaper biosimilars (drugs designed to have the same pharmacodynamic and pharmacokinetic properties as their previously licensed reference drugs) are available, but were not tested in patients with psoriasis. 3,4 Most regulatory agencies have approved the use of infliximab biosimilars for the treatment of psoriasis by extrapolating efficacy from studies in other diseases.…”

Biologics in patients with skin diseases

“…[17][18][19] Because the aforementioned FDA-approved mAbs find their utility and efficacy in patients with moderate-to-severe psoriasis, they are widely prescribed, and the associated financial burden is increasing. 20 The biosimilars for the 3 anti-TNF-a etanercept (Erelzi; Sandoz, Holzkirchen, Germany), adalimumab (Amjevita; Amgen), and infliximab (Inflectra; Hospira, Lake Forest, Ill) have been officially FDA approved since 2016 and represent a potential cost savings. [21][22][23] Biologics are large and complex molecules that can never be exactly duplicated because of their inherent variability.…”